Zydus receives USFDA final approval for Bisoprolol Fumarate and Hydrochlorothiazide tablets | Tech Reddy

Zydus Lifesciences has received approval from the United States Food and Drug Administration (USFDA) for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, 10 mg/6.25 mg (USRLD : Ziac tablets) received final marketing approval.

The combination of bisoprolol fumarate and hydrochlorothiazide is indicated for the treatment of high blood pressure (hypertension).

The drug is manufactured at the group’s formulation plant in Ahmedabad SEZ, India.

Bisoprolol fumarate and hydrochlorothiazide tablets had annual sales of $27.1 million in the United States, according to IQVIA (IQVIA MAT 2022).

Powered by Capital Market – Live

(This story was not edited by Business Standard staff and was generated automatically from a syndicated feed.)